<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03592004</url>
  </required_header>
  <id_info>
    <org_study_id>ZLiu</org_study_id>
    <nct_id>NCT03592004</nct_id>
  </id_info>
  <brief_title>Radiomics of Mp-MRI Assessing NAC Outcome in Breast Cancer</brief_title>
  <official_title>Radiomics of Multiparametric MRI for Neoadjuvant Chemotherapy Outcomes Assessment in Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese Academy of Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Guangdong Provincial People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cancer Institute and Hospital, Chinese Academy of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beijing Friendship Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Yunnan Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Liaoning Tumor Hospital &amp; Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>First Hospital of China Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Affiliated Hospital of Hebei University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Chinese Academy of Sciences</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single-arm, multicentre study that aims to assess whether Radiomics combining
      multiparametric MRI and clinical data could be a good predictor of the responses to
      neoadjuvant chemotherapy in Breast Cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients undergo multiparametric MRI (including T2WI, DWI and DCE-MRI) at baseline, after 2
      courses of neoadjuvant chemotherapy, and prior to the surgery at least 8 weeks after the
      treatment procedure. Patients undergo biopsy test in one week after the baseline MRI scan to
      detect the biomarkers including ER, PR, Her-2 and Ki-67, which can be used to select the
      treatment plan referring to the NCCN clinical guidelines. After the surgery, responses to
      neoadjuvant chemotherapy are determined according to the histopathologically examination of
      the surgically resected specimens.

      After completion of treatment procedure, patients are followed up for 5 years.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">July 18, 2018</start_date>
  <completion_date type="Anticipated">June 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>predicting pathological complete response (pCR) or no response (NR)</measure>
    <time_frame>20 weeks</time_frame>
    <description>The value of Radiomics of multiparametric MRI in predicting responses to neoadjuvant chemotherapy, including pathological complete response (pCR) and no response (NR).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>5 years for Disease free survival</measure>
    <time_frame>5 years</time_frame>
    <description>The association between Radiomics of multiparametric MRI and disease free survival (DFS), which defined as the time from the beginning of neoadjuvant chemotherapy to the confirmed time of recurrence or metastatic disease, or death due to any other cause.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>5 years for Overall survival</measure>
    <time_frame>5 years</time_frame>
    <description>The association between Radiomics of multiparametric MRI and overall survival (OS), which defined as the time from the beginning of neoadjuvant chemotherapy to the death with any causes.</description>
  </primary_outcome>
  <number_of_groups>7</number_of_groups>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Breast Cancer</condition>
  <condition>Radiomics</condition>
  <condition>Neoadjuvant Chemotherapy</condition>
  <condition>Multi-parametric MRI</condition>
  <arm_group>
    <arm_group_label>Guangdong General Hospital</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Cancer Hospital Chinese Academy Of Medical Sciences</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Beijing Friendship Hospital</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Yunnan Cancer Hospital</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Liaoning Cancer Hospital</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>The First Hospital Of China Medical University</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Affiliated Hospital Of Hebei University</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>neoadjuvant chemotherapy</intervention_name>
    <description>neoadjuvant chemotherapy</description>
    <arm_group_label>Affiliated Hospital Of Hebei University</arm_group_label>
    <arm_group_label>Beijing Friendship Hospital</arm_group_label>
    <arm_group_label>Cancer Hospital Chinese Academy Of Medical Sciences</arm_group_label>
    <arm_group_label>Guangdong General Hospital</arm_group_label>
    <arm_group_label>Liaoning Cancer Hospital</arm_group_label>
    <arm_group_label>The First Hospital Of China Medical University</arm_group_label>
    <arm_group_label>Yunnan Cancer Hospital</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Chinese
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  biopsy-proven invasive breast cancer;

          -  received complete neoadjuvant chemotherapy and no treatment has been done before;

          -  surgery was performed after completion of neoadjuvant chemotherapy, after which pCR
             was confirmed by postoperative pathological examination;

          -  pretreatment MRI data within a month before the start of the treatment was eligible,
             including T2WI, DWI and DCE-MRI.

        Exclusion Criteria:

          -  not completing neoadjuvant chemoradiotherapy;

          -  not undergoing surgery at our hospital, or pCR was not assessed;

          -  lack of T2WI, or DWI or DCE-MRI data;

          -  insufficient MRI quality to obtain measurements (e.g., owing to motion artifacts);

          -  had unilateral multifocal cancers, and the correlation between the tumor in MR images
             and postoperative pathological examination was uncertain.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jie Tian, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chinese Academy of Sciences</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Zhenyu Liu, Doctor</last_name>
    <phone>8613466358609</phone>
    <email>zhenyu.liu@ia.ac.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Zhenyu Liu</name>
      <address>
        <city>Beijing</city>
        <zip>100190</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhenyu Liu, Doctor</last_name>
      <phone>8613466358609</phone>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2018</verification_date>
  <study_first_submitted>June 26, 2018</study_first_submitted>
  <study_first_submitted_qc>July 17, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 19, 2018</study_first_posted>
  <last_update_submitted>July 17, 2018</last_update_submitted>
  <last_update_submitted_qc>July 17, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">July 19, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chinese Academy of Sciences</investigator_affiliation>
    <investigator_full_name>Zhenyu Liu</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

